Interviews

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, addresses challenges in identifying patients with generalized pustular psoriasis (GPP) and how artificial intelligence (AI) can help alleviate these concerns.

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, shares the importance of incorporating a culture of well-being within oncology practices.

Legal expert in health care, partner, and cochair of the health care coverage and reimbursement practice at Foley Hoag LLP, Ross Margulies discusses his excitement and expectations as a featured speaker at the upcoming 2024 AMCP Annual Conference.

Pat Van Burkleo, the executive director of Feeding Louisiana, the Louisiana Food Bank Association, shares insight on legislative priorities and the impact food insecurity can have on health.

Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses implementing value-based care initiatives in a pediatric dermatology practice.

Mitzi Joi Williams, MD, of Joi Life Wellness Multiple Sclerosis (MS) Center, lists challenges in recruiting and retaining minority populations for clinical trials and discusses ways to ensure clinical trial accessibility.

To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.

Lawrence Eichenfield, MD, of Rady Children's Hospital - San Diego, discusses the implications of the findings from INTEGUMENT-PED, the phase 3 study assessing the efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients with atopic dermatitis (AD).

Krystyn Van Vliet, PhD, of Cornell University, discusses the scalability of 3D platforms in multiple sclerosis (MS) drug discovery and compares their costs with those of other drug discovery methods.

Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the potential of a disease-modifying therapy in polycythemia vera, treating high-risk vs low-risk patients, and emerging therapies in the pipeline.

"The government really didn't rise to the challenge the way that it should have,” notes Ben Jones, vice president of government relations and public policy for The US Oncology Network. “Practices were in distress…stretching all resources to figure out workarounds."

Michael Morse, MD, FACP, MHS, professor of medicine at Duke University School of Medicine and medical oncologist at Duke Cancer Center, spoke to the evolution of hepatocellular carcinoma (HCC) treatment in recent years, as well as ongoing research with potential to impact clinical practice.

Will Shapiro, vice president of data science at Flatiron Health, explains the different ethical challenges associated with various forms of artificial intelligence models used in oncology care.

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, is 1 of 6 cochairs for the 2024 Community Oncology Conference, and here she discusses how meeting content has incorporated ongoing coverage of the extremely disruptive cyberattack and how there is still so much work to be done.

Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, discusses a recent class-action lawsuit brought against Johnson & Johnson in which an employee alleged a breach of fiduciary duty regarding her employer-sponsored pharmacy benefits.

Judy Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance (COA), addresses the challenges pharmacies face in managing formularies to provide optimal patient care.

After moderating the panel discussion at The American Journal of Managed Care®’s Institute for Value-Based Medicine® (IVBM) event held in partnership with Banner|Aetna, Sandra Stein, MD, chief medical officer of Banner Health Plans, shared her key takeaway.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, discusses ways that AI is being integrated into personalized medicine for patients with generalized pustular psoriasis (GPP).

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, discusses the impact of peer support groups within a health care organization and its patients.

Julie Patterson, PharmD, PhD, senior director of research at the National Pharmaceutical Council, discussed potential impact of the Inflation Reduction Act of 2022 (IRA) on small molecule drug research and development investments toward subsequent indications.

Pat Van Burkleo, executive director of Feeding Louisiana, shares the key topics addressed during the Ochsner Health IVBM panel discussion on initiatives to increase food access in communities across the state.

Monica Li, MD, medical and cosmetic dermatologist, listed microneedling considerations and precautions so that providers can safely implement the procedure.

Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences, discusses atopic dermatitis (AD) diagnosis and treatment differences in children vs adults.

On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.

"If someone is food insecure for a long period of time, then they may be consuming foods that aren't as nutritious and support their health and growth as they should," Denise Holston, PhD, explains in an interview.

Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, described monitoring protocols for clinicians when using oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

Despite the positive week 48 results when used to treat moderate to severe hidradenitis suppurativa (HS), Jeff Stark, MD, of Union Chimique Belge, noted that bimekizumab is still considered an investigational therapy for HS treatment as it has not yet received an FDA approval.

Despite being used for decades, there continues to be emerging data on interferons and how they should be used in patients with myeloproliferative neoplasms (MPNs), explains Raajit Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center.

With the 2024 Community Oncology Conference, from the Community Oncology Alliance (COA), set to kick off this week in Orlando, Florida, The American Journal of Managed Care® spoke with Emily Touloukian, DO, COA board member and 1 of 6 cochairs for this year’s meeting, on highlights from the packed agenda and the power of advocacy.

For World Bipolar Day, Roger Rivera, DNP, board-certified PMHNP, shares his insight on integrating psychotherapeutic techniques and medication regimens for bipolar disorder.